Cas No.: | 1629138-41-5 |
Synonyms: | SRI-011381; SRI 011381; SRI011381 |
SMILES: | O=C(NC1CCCCC1)N(CC2=CC=CC=C2)CC3CCNCC3.Cl[H] |
Formula: | C20H32ClN3O |
M.Wt: | 365.94 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks4°C in DMSO,6 months-80°C in DMSO |
Description: | SRI-011381 is an orally active TGF-β signaling agonist, exhibits neuroprotective effects[1][2]. |
In Vivo: | SRI-011381 (30 mg/kg; i.p.; every 2 d; for 22 days) partially rescues the deficits in optic nerve and retina of YAPGFAP-CKO EAE mice[2]. Animal Model: YAPGFAP-CKO mice bearing experimental autoimmune encephalomyelitis (EAE)[2] Dosage: 30 mg/kg Administration: Intraperitoneally injection; every 2 d; for 22 days Result: Significantly inhibited inflammatory infiltration and relieved the loss of neurons in YAPGFAP-CKO EAE mice. |
In Vitro: | SRI-011381 (10 μM) promotes the proliferation of mouse lung fibroblasts, and significantly increases TGF-β1, NALP3, collagen-1, and α-SMA expression[1]. |
References: | [1]. Jingyin Han, et al. The Improvement Effect of Sodium Ferulate on the Formation of Pulmonary Fibrosis in Silicosis Mice Through the Neutrophil Alkaline Phosphatase 3 (NALP3)/Transforming Growth Factor-β1 (TGF-β1)/α-Smooth Muscle Actin (α-SMA) Pathway. Med Sci Monit. 2021 Jun 15;27:e927978. [2]. Qian Wu, et al. Astrocytic YAP protects the optic nerve and retina in an experimental autoimmune encephalomyelitis model through TGF-β signaling. Theranostics. 2021 Jul 25;11(17):8480-8499. |